AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

“Straight out of the blocks,” he says, “Cambridge Wide Open Week has been a whirlwind of inspiring pitches, thought-provoking ...

After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge ... could one day become a biotech hub to rival Boston and San Francisco in ...

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

The biopharma’s planned R&D center in Cambridge—which is the home of AstraZeneca and already a U.K. biotech hub in its own right—will have space for around 90 scientists and focus on ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Which AstraZeneca's product candidate has the potential to become a 'blockbuster'? From the Cambridge-based company's cardiovascular portfolio, the most promising experimental drug I highlight is ...

IonQ (IONQ) announced results of a research program between the company, AstraZeneca (AZN), Amazon Web Services (AMZN) and Nvidia (NVDA).